Articles
Austin, TX-Oncology formulary management is a complex process requiring a structured approach and multidisciplinary engagement, according to Lindsey B. Amerine, PharmD, MS, BCPS, who spoke at the 11th annual Hematology/Oncology Pharmacy Association conference.
By Wayne Kuznar
Washington, DC-The role of oncology specialty pharmacy in helping to streamline medication delivery for patients with cancer was the subject of a panel discussion that took place at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
By Chase Doyle
Despite the promise of molecular profiling, approximately 80% of patients with lung cancer lack a defined genotypic mutation, and become resistant when treated with a tyrosine kinase inhibitor.
Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015.
Austin, TX-Three advanced azole agents are now being used to treat invasive aspergillosis, and strengths and weaknesses exist for each of them, according to research presented by James S. Lewis II, PharmD, at the 11th annual Hematology/Oncology Pharmacy Association conference.
Boston, MA-Rociletinib, a specially engineered third-generation EGFR inhibitor, is accumulating an impressive track record in early studies of non-small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the T790M mutation, a heretofore patient population with unmet needs. T790M, the most common mutation associated with resistance to first-line EGFR-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs.
As a healthcare professional with substantial income-or income potential, you will most likely be contacted by a number of individuals offering various types of financial products and services throughout your career.
Elotuzumab (Empliciti) (elotuzumab) has been approved for use in combination with lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma who have received 1 to 3 prior medications. Daratumumab (Darzalex) is the only other US Food and Drug Administration-approved monoclonal antibody for patients with this type of cancer.
Necitumumab (Portrazza) has been approved in combination with 2 forms of chemotherapy for patients with metastatic, squamous non–small-cell lung cancer (NSCLC) who have not received previous treatment for their cancer.
Copenhagen, Denmark-Intravenous (IV) iron isomaltoside 1000 (Monofer) demonstrated sustained increases in hemoglobin (Hb) and fewer adverse events compared with oral iron sulphate in patients with chemotherapy-induced anemia (CIA), according to research presented by Gunnar Birgegard, MD, PhD, and colleagues at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.